Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of the participants to the population-based Australian Breast Cancer Family Registry that were genotyped for RNASEL:p.Glu265*

From: Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?

  Cases (n = 1445) Controls (n = 827)
Age at diagnosis (years) 42 [23–59] n/a
Age at recruitment (years) 43 [23–60] 41 [20–60]
Ethnicity
 White/Caucasian 1345 (93%) 710 (85.9%)
 Asian and Pacific Islander 85 (5.9%) 32 (3.9%)
 Other 8 (0.6%) 7 (0.8%)
 Unknown 7 (0.5%) 78 (9.4%)
Laterality
 Right breast 713 (49.3%) n/a
 Left breast 732 (50.7%) n/a
Estrogen Receptor Status
 Negative 439 (30.4%) n/a
 Positive 815 (56.4%) n/a
 Unknown 191 (13.2%) n/a
Grade
 GI 212 (14.6%) n/a
 GII 526 (36.4%) n/a
 GIII 555 (38.4%) n/a
 GIV 3 (0.2%) n/a
 Unknown 149 (10.4%) n/a
  1. n/a: not applicable
  2. GI, grade I; GII, grade II; GIII, Grade III; GIV, Grade IV